caspase8 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
caspase8
Caspase8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 4194 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caspase8/Caspase-8+Antibody/pm41839256-67-8-21
Average 96 stars, based on 4194 article reviews
Caspase8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 4194 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caspase8/Caspase-8+Antibody/pm41839256-67-8-21
Average 96 stars, based on 4194 article reviews
caspase8 - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Incubation:Article Title: Epithelial Gab1 Restricts Sepsis‐Induced Intestinal Injury by Orchestrating TNF/NF‐κB Axis Article Snippet: Samples were separated by SDS‐PAGE gels and transferred onto nitrocellulose membranes (Pall). .. The membranes were then incubated overnight at 4°C with primary antibodies including Gab1 (Proteintech, 26200‐1‐AP, 1:1000), phospho‐p65 (Ser536) (CST, 3033, 1:1000), p65 (CST, 8242, 1:1000), phospho‐ERK (Thr202/Tyr204) (CST, 4370, 1:1000), ERK1/2 (CST, 4695, 1:1000), phospho‐p38 (Thr180/Tyr182) (CST, 4511, 1:1000), p38 (Proteintech, 14064‐1‐AP, 1:1000) cl‐Caspase3 (CST, 9664, 1:1000), Caspase3 (CST, 9662, 1:1000), Article Title: Inhibition of microRNA-126-3p attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway. Article Snippet: MicroRNA-126 (miR-126) has emerged as a potential key regulator in ischemic stroke.. Yet, its exact mechanism of action is still unexplored.. This study aims to investigate whether miR-126 targets and regulates the low-density lipoprotein receptor-related protein (LRP6), an important co-receptor in the Wnt/β-catenin signaling pathway, to reduce ischemic brain injury in mice. Blocking Assay:Article Title: Inhibition of microRNA-126-3p attenuates ischemic stroke by targeting endogenous neuroprotective receptor LRP6 in the Wnt/β-catenin signaling pathway. Article Snippet: MicroRNA-126 (miR-126) has emerged as a potential key regulator in ischemic stroke.. Yet, its exact mechanism of action is still unexplored.. This study aims to investigate whether miR-126 targets and regulates the low-density lipoprotein receptor-related protein (LRP6), an important co-receptor in the Wnt/β-catenin signaling pathway, to reduce ischemic brain injury in mice. Western Blot:Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. Control:Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. Bioprocessing:Article Title: African swine fever virus A179L inhibits interferon induced transmembrane protein 1 activation of NF-κB pathway Article Snippet: .. The following murine monoclonal antibodies were used: P30 (CP204L) was prepared and supplied by our laboratory; HA (AE008), FLAG (AE061) (Abclonal); GAPDH (10494-1-AP; Proteintech); Caspase3 (#9502), Article Title: Bacoside-A enhances temozolomide-induced cytotoxicity in U87MG glioblastoma cells via ROS-mediated apoptosis and EGFR/MAPK inhibition. Article Snippet: Temozolomide (TMZ) is the primary chemotherapeutic agent for glioblastoma multiforme (GBM), but its effectiveness is limited by resistance, recurrence, and toxicity.. Combining natural compounds with TMZ is a promising approach to overcome these challenges.. Bacoside-A, a brain tonic derived from Bacopa monnieri with proven anticancer properties, was evaluated for its chemotherapeutic potential in U87MG cells. |